Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.35 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707877 | 0.83 | S1PR1 (0.39) | CYP1A2CYP2C19S1PR1ALDH1A1MAPT | |
| SCHEMBL5580492 | 0.82 | KDM4E (0.42) | KDM4ELMNAPDE4APDE4BPDE4C | |
| Methoxymethane SCHEMBL28378286 | 0.80 | S1PR1 (0.37) | KDM4ECYP1A2CYP2C19PDE4APDE4B | |
| SCHEMBL16954953 | 0.79 | ALDH1A1 (0.42) | KDM4ECYP2C9LMNACYP1A2PDE10A | |
| SCHEMBL5109093 | 0.79 | EPAS1 (0.35) | KDM4ECYP2C9LMNACYP1A2CYP3A4 | |
| SCHEMBL9929711 | 0.78 | MEN1 (0.42) | KDM4ECYP2C9LMNACYP1A2CYP3A4 | |
| SCHEMBL5104144 | 0.77 | TSHR (0.42) | KDM4ELMNAALDH1A1HPGDALOX15 | |
| SCHEMBL2122930 | 0.77 | CYP2C9 (0.41) | KDM4ECYP2C9LMNACYP1A2CYP3A4 | |
| SCHEMBL10009328 | 0.77 | CTSS (0.40) | CYP1A2CYP2C19S1PR1ALDH1A1MAPT | |
| SCHEMBL14277303 | 0.76 | MAPK1 (0.41) | KDM4ECYP2C9LMNACYP1A2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1651629-A1 | SUBSTITUTED BENZOTHIOPHENE COMPOUNDS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050038104-A1 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012283-A1 | SUBSTITUTED BENZOTHIOPHENE COMPOUNDS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038104-A1 | Substitute benzothiophene compounds | TST, SULT1E1, LTC4S | KDM4E 2321/4885CYP2C9 282/4885LMNA 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.